Recall events
/
Event 89808
Event summary
Timeline bucket March 23, 2022
Product types Drug
Classifications Class II
Statuses Terminated
Recalling firm wording Drug Depot, Inc., dba APS Pharmacy
Dossier provenance
Source snapshots represented here
openFDA Drug Enforcement
Report-date coverage
June 20, 2012–July 08, 2026
Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.
Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.
How coverage and grouping work
Device root-cause evidence is not applicable to this event.
No grouped product has the official product type device; this is not an unavailable-enrichment finding.
Complete imported group
Every recalled product in this event
8 official enforcement rows
Product dates, classifications, firms, and source wording remain attached to their individual rows.
Opening this dossier never hides products that did not match a prior timeline filter.
drug · product 1 of 8
GONADORELIN (5ML) 0.2 MG/ML INJECTABLE, Packaged in a multi dose 10ML vial, Formula ID132227, APS Pharmacy
D-0728-2022
Recall number D-0728-2022
Initiated March 23, 2022
Classification Class II
Status Terminated
Quantity 6017 vials
App-derived interpretation
Sterility assurance
reason.sterility_assurance · v1.0.0
Lack of sterility
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Lack of sterility assurance.
Code information Lots: 745708 BUD: 6/21/2022; 753364 BUD: 7/27/2022; 752508 BUD: 7/24/2022; 750313 BUD: 7/16/2022; 753020 BUD: 7/26/2022; 747712 BUD: 7/4/2022; 747974 BUD: 7/5/2022; 754802 BUD: 8/3/2022; 751158 BUD: 7/19/2022; 756837 BUD: 8/16/2022; 748939 BUD: 7/10/2022; 750842 BUD: 7/18/2022; 755742 BUD: 8/8/2022; 758691 BUD: 8/28/2022; 758432 BUD: 8/27/2022; 758975 BUD: 8/29/2022; 756643 BUD: 8/15/2022
Distribution pattern Nationwide in the USA including Puerto Rico.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[12675]
FDA event record
· Exact recall-number query on openFDA
drug · product 2 of 8
(CA) GONADORELIN (4ML) 0.2 MG/ML INJECTABLE, Packaged in a multi dose 10ML vial, Formula ID136345, APS Pharmacy
D-0729-2022
Recall number D-0729-2022
Initiated March 23, 2022
Classification Class II
Status Terminated
Quantity 1843 vials
App-derived interpretation
Sterility assurance
reason.sterility_assurance · v1.0.0
Lack of sterility
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Lack of sterility assurance.
Code information Lots: 749842 BUD: 7/13/2022; 749568 BUD: 7/12/2022; 752053 BUD: 7/23/2022; 752817 BUD: 7/25/2022; 757404 BUD: 8/21/2022; 757915 BUD: 8/23/2022; 757321 BUD: 8/20/2022; 753718 BUD: 7/30/2022
Distribution pattern Nationwide in the USA including Puerto Rico.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[12549]
FDA event record
· Exact recall-number query on openFDA
drug · product 3 of 8
TESTOSTERONE CYPIONATE/ANASTROZOLE *GS* OIL 200MG/1MG/ML Injectable, Packaged in a multi dose 10ML vial, as a) 4 ML Formula ID 115387; b) (RM) 10 ML Formula ID 115125; APS Pharmacy
D-0730-2022
Recall number D-0730-2022
Initiated March 23, 2022
Classification Class II
Status Terminated
Quantity 846 vials
App-derived interpretation
Sterility assurance
reason.sterility_assurance · v1.0.0
Lack of sterility
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Lack of sterility assurance.
Code information Lots: a) 745383 BUD: 6/20/2022; 759295 BUD: 8/30/2022; b) 745749 BUD: 6/21/2022; 746272 BUD: 6/27/2022
Distribution pattern Nationwide in the USA including Puerto Rico.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[12590]
FDA event record
· Exact recall-number query on openFDA
drug · product 4 of 8
TESTOSTERONE CYPIONATE/ ANASTROZOLE *GS* OIL (10ML) 200MG/0.5MG/ML; Packaged in a multi dose 10ML vial, as a) (CA) 4 ML Formula ID 136164; b) (RM) 10 ML Formula ID 115962; APS Phar
D-0731-2022
Recall number D-0731-2022
Initiated March 23, 2022
Classification Class II
Status Terminated
Quantity 73 vials
App-derived interpretation
Sterility assurance
reason.sterility_assurance · v1.0.0
Lack of sterility
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Lack of sterility assurance.
Code information Lots: a)750851 BUD: 7/18/2022; b) 754549 BUD: 8/2/2022
Distribution pattern Nationwide in the USA including Puerto Rico.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[12606]
FDA event record
· Exact recall-number query on openFDA
drug · product 5 of 8
TESTOSTERONE CYPIONATE/ DHEA *GS* 200/10MG/ML Injectable, Packaged in a multi dose 10ML vial, as a) 5 ML Formula ID 115678; b) 10 ML Formula ID 115498, APS Pharmacy
D-0732-2022
Recall number D-0732-2022
Initiated March 23, 2022
Classification Class II
Status Terminated
Quantity 620 vials
App-derived interpretation
Sterility assurance
reason.sterility_assurance · v1.0.0
Lack of sterility
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Lack of sterility assurance.
Code information Lots: a)746000 BUD: 6/26/2022; b) 751472 BUD: 7/20/2022
Distribution pattern Nationwide in the USA including Puerto Rico.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[12581]
FDA event record
· Exact recall-number query on openFDA
drug · product 6 of 8
TESTOSTERONE CYPIONATE/PROPIONATE *SES* Oil (10 ML) 160MG/20MG/ML Injectable, Packaged in a multi dose 10ml vial, Formula ID 115498, APS Pharmacy
D-0733-2022
Recall number D-0733-2022
Initiated March 23, 2022
Classification Class II
Status Terminated
Quantity 0
App-derived interpretation
Sterility assurance
reason.sterility_assurance · v1.0.0
Lack of sterility
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Lack of sterility assurance.
Code information Lot:759312 BUD: 8/30/2022
Distribution pattern Nationwide in the USA including Puerto Rico.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[12585]
FDA event record
· Exact recall-number query on openFDA
drug · product 7 of 8
TESTOSTERONE CYPIONATE *GS* Oil 200 MG/ML Injectable, Packaged in a multi dose 10ML vial, Formula ID 76681, APS Pharmacy
D-0734-2022
Recall number D-0734-2022
Initiated March 23, 2022
Classification Class II
Status Terminated
Quantity 24 vials
App-derived interpretation
Sterility assurance
reason.sterility_assurance · v1.0.0
Lack of sterility
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Lack of sterility assurance.
Code information Lot: 754381 BUD: 8/1/2022
Distribution pattern Nationwide in the USA including Puerto Rico.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[12548]
FDA event record
· Exact recall-number query on openFDA
drug · product 8 of 8
TESTOSTERONE CYPIONATE *GS* (2 mL) 80 MG/ML Injectable, Packaged in a multi dose 10ML vial, Formula ID 127492, APS Pharmacy
D-0735-2022
Recall number D-0735-2022
Initiated March 23, 2022
Classification Class II
Status Terminated
Quantity 17 vials
App-derived interpretation
Sterility assurance
reason.sterility_assurance · v1.0.0
Lack of sterility
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Lack of sterility assurance.
Code information Lot: 746269 BUD: 6/27/2022
Distribution pattern Nationwide in the USA including Puerto Rico.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[12639]
FDA event record
· Exact recall-number query on openFDA
